

*Appendix Table 8. Effects of Serotonin and the Noradrenaline Reuptake Inhibitor Duloxetine on Stress UI : Results from Randomized Controlled Clinical Trials (70)**

Author Year	Daily Dose of Duloxetine	Control Treatment	Outcomes	(Events/Active Treatment) [Events/Control Treatment]	Relative Risk (95% CI)	Risk Difference (95% CI)	Quality
Dmochowski, 2003(71)	80mg	Placebo NT	Failure to cure	(308/344) [319/339]	0.95 (0.91; 1.00)	-0.05 (-0.09; 0.00)	Intention to treat. Double blind. Allocation concealment adequate. Sample size not justified.
Millard, 2004(72)	80mg	Placebo or NT	Failure to cure	(211/227) [217/231]	0.99 (0.94; 1.04)	-0.01 (-0.06; 0.04)	Intention to treat. Double blind. Allocation concealment adequate. Sample size justified
Norton, 2002(73)	80mg	Placebo or NT	Failure to cure	(100/123) [112/132]	0.96 (0.86; 1.07)	-0.04 (-0.13; 0.06)	Intention to treat. Double blind. Allocation concealment adequate. Sample size justified
	40mg	Placebo or NT	Failure to cure	(93/123) [112/132]	0.89 (0.79; 1.01)	-0.09 (-0.19; 0.01)	
	20mg	Placebo or NT	Failure to cure	(107/128) [112/132]	0.99 (0.89; 1.09)	-0.01 (-0.10; 0.08)	
Cardozo, 2004(74)	80mg	Placebo or NT	Failure to improve	(16/46) [45/52]	0.40 (0.27; 0.61)	-0.52 (-0.68; -0.35)	Intention to treat. Double blind. Allocation concealment adequate. Sample size justified
Dmochowski, 2003(71)	80mg	Placebo or NT	Failure to improve	(167/344) [225/339]	0.73 (0.64; 0.84)	-0.18 (-0.25; -0.11)	Intention to treat. Double blind. Allocation concealment adequate. Sample size not justified.
Millard, 200(72)	80mg	Placebo or NT	Failure to improve	(92/227) [100/231]	0.94 (0.75; 1.16)	-0.03 (-0.12; 0.06)	Intention to treat. Double blind. Allocation concealment adequate. Sample size justified
Van Kerrebroeck, 2004(75)	80mg	Placebo or NT	Failure to improve	(119/247) [164/247]	0.73 (0.62; 0.85)	-0.18 (-0.27; -0.10)	Intention to treat. Double blind. Allocation concealment adequate. Sample size justified

Zinner, 1998(77)	40mg	Placebo or NT	Failure to improve	(18/33) [29/34]	0.64 (0.45; 0.90)	-0.31 (-0.51; -0.10)	Intention to treat. Double blind. Allocation concealment unclear. Sample size justified
Mulcahy, 1996(76)	20mg	Placebo or NT	Failure to improve	(13/55) [19/37]	0.46 (0.26; 0.81)	-0.28 (-0.47; -0.08)	No Intention to treat. Double blind. Allocation concealment unclear. Sample size justified
Zinner, 1998(77)	20mg	Placebo or NT	Failure to improve	(18/34) [29/34]	0.62 (0.44; 0.88)	-0.32 (-0.53; -0.12)	Intention to treat. Double blind. Allocation concealment unclear. Sample size justified
	30mg	Placebo or NT	Failure to improve	(10/26) [29/34]	0.45 (0.27; 0.75)	-0.47 (-0.69; -0.25)	Intention to treat. Double blind. Allocation concealment unclear. Sample size justified
Norton, 2002(73)	80mg	Placebo or NT	Failure to cure (objective - SPT)	(69/113) [72/114]	0.97 (0.79; 1.18)	-0.02 (-0.15; 0.11)	Intention to treat. Double blind. Allocation concealment adequate. Sample size justified
	40mg	Placebo or NT	Failure to cure (objective - SPT)	(63/111) [72/114]	0.90 (0.73; 1.11)	-0.06 (-0.19; 0.06)	
	20mg	Placebo or NT	Failure to cure (objective - SPT)	(75/110) [72/114]	1.08 (0.89; 1.30)	0.05 (-0.07; 0.17)	
	80mg	Placebo or NT	Failure to cure (objective - CST)	(96/114) [103/118]	0.96 (0.87; 1.07)	-0.03 (-0.12; 0.06)	
	40mg	Placebo or NT	Failure to cure (objective - SPT)	(86/112) [103/118]	0.88 (0.78; 0.99)	-0.11 (-0.20; -0.01)	
	20mg	Placebo or NT	Failure to cure (objective - CST)	(101/112) [103/118]	1.03 (0.94; 1.13)	0.03 (-0.05; 0.11)	
Dmochowski, 2003(71)	80mg	Placebo or NT	Failure to cure (objective - diary)	(308/344) [319/339]	0.95 (0.91; 1.00)	-0.05 (-0.09; 0.00)	Intention to treat. Double blind. Allocation concealment adequate. Sample size not justified.
Millard, 2004(72)	80mg	Placebo or NT	Failure to cure (objective - diary)	(211/227) [217/231]	0.99 (0.94; 1.04)	-0.01 (-0.06; 0.04)	Intention to treat. Double blind. Allocation concealment adequate. Sample size justified
Norton, 2002(73)	80mg	Placebo or NT	Failure to cure (objective - diary)	(100/123) [112/132]	0.96 (0.86; 1.07)	-0.04 (-0.13; 0.06)	Intention to treat. Double blind. Allocation concealment adequate. Sample size justified
	40mg	Placebo or NT		(93/123) [112/132]	0.89 (0.79; 1.01)	-0.09 (-0.19; 0.01)	
	20mg	Placebo or NT		(107/128) [112/132]	0.99 (0.89; 1.09)	-0.01 (-0.10; 0.08)	

Cardozo, 2004(74)	80mg	Placebo or NT	Status ('very much better,' 'much better,' or 'a little better' from PGI-I)	(17/51) [4/52]	4.33 (1.57; 12.00)	0.26 (0.11; 0.40)	Intention to treat. Double blind. Allocation concealment adequate. Sample size justified	
Kinchen, 2005(128)	80mg	Placebo or NT	Status ('very much better,' 'much better,' or 'a little better' from PGI-I)	(110/224) [93/227]	1.20 (0.98; 1.47)	0.08 (-0.01; 0.17)	No Intention to treat. Double blind. Allocation concealment adequate. Sample size justified	
Millard, 2004(72)	80mg	Placebo or NT	Status ('very much better,' 'much better,' or 'a little better' from PGI-I)	(167/227) [148/231]	1.15 (1.01; 1.30)	0.09 (0.01; 0.18)	Intention to treat. Double blind. Allocation concealment adequate. Sample size justified	
Norton, 2002(73)	80mg	Placebo or NT	Status ('very much better,' 'much better,' or 'a little better' from PGI-I)	(62/140) [37/138]	1.65 (1.18; 2.30)	0.17 (0.06; 0.29)	Intention to treat. Double blind. Allocation concealment adequate. Sample size justified	
Van Kerrebroeck, 2004(75)	80mg	Placebo or NT	Status ('very much better,' 'much better,' or 'a little better' from PGI-I)	(139/247) [119/247]	1.17 (0.99; 1.38)	0.08 (0.01; 0.17)	Intention to treat. Double blind. Allocation concealment adequate. Sample size justified	
Ghoniem 2005(78)	80mg + PFMT	Placebo	Numbers not cured (objective - diary)	(17/44) [33/44]	0.52 (0.34;0.78)	-0.36 (-0.56; -0.17)	Intention to treat. Double blind.	
	80mg	Pelvic Floor Muscle Training		(20/46) [34/46]	0.59 (0.41;0.85)	-0.30 (-0.50; -0.11)	Allocation concealment adequate. Sample size justified	
Steers† 2007(129)	120mg	Placebo	Status ('very much better,' 'much better' or 'a little better' from PGI-I)	(81/153) [63/153]	1.29 (1.01;1.64)	0.12 (0.01; 0.23)	Intention to treat. Double blind. Allocation concealment unclear. Sample size justified	
Norton, 2002(73)	40mg	Placebo or NT	Status ('very much better,' 'much better,' or 'a little better' from PGI-I)	(51/137) [37/138]	1.39 (0.98; 1.97)	0.10 (-0.01; 0.21)	Intention to treat. Double blind. Allocation concealment adequate.	
	20mg	Placebo or NT		(43/138) [37/138]	1.16 (0.80; 1.68)	0.04 (-0.06; 0.15)	Sample size justified	
	80mg	Duloxetine 40mg		Failure to cure (quantification of symptoms)	(100/123) [93/123]	1.08 (0.94; 1.23)	0.06 (-0.05; 0.16)	
	80mg	Duloxetine 20mg			(100/123) [107/128]	1.08 (0.94; 1.23)	-0.02 (-0.12; 0.07)	

	80mg	Duloxetine 20mg		(100/123) [107/128]	0.97 (0.87; 1.09)	-0.02 (-0.12; 0.07)	
	40mg	Duloxetine 20mg		(93/123) [107/128]	0.90 (0.80; 1.03)	-0.08 (-0.18; 0.02)	
Zinner, 1998(77)	30mg	Duloxetine 20mg	Failure to cure (quantification of symptoms)	(10/26) [18/34]	0.73 (0.41; 1.30)	-0.14 (-0.40; 0.11)	Intention to treat. Double blind. Allocation concealment unclear. Sample size justified
	40mg	Duloxetine 20mg		(18/33) [18/34]	1.03 (0.66; 1.61)	0.02 (-0.22; 0.25)	
	40mg	Duloxetine 30mg		(18/33) [10/26]	1.42 (0.80; 2.53)	0.16 (-0.09; 0.41)	
Norton, 2002(73)	80mg	Duloxetine 40mg	Failure to cure (objective - SPT)	(6/113) [63/111]	1.08 (0.86; 1.34)	-0.51 (-0.62; -0.41)	Intention to treat. Double blind. Allocation concealment adequate. Sample size justified
	80mg	Duloxetine 20mg		(69/113) [75/110]	0.90 (0.74; 1.09)	-0.07 (-0.20; 0.05)	
	40mg	Duloxetine 20mg	Failure to cure (objective - CST)	(63/111) [75/110]	0.83 (0.68; 1.02)	-0.11 (-0.24; 0.01)	
	80mg	Duloxetine 40mg		(96/114) [86/112]	1.10 (0.96; 1.25)	0.07 (-0.03; 0.18)	
	80mg	Duloxetine 20mg	Failure to cure (objective - diary)	(96/114) [101/112]	0.93 (0.84; 1.03)	-0.06 (-0.15; 0.03)	
	40mg	Duloxetine 20mg		(86/112) [101/112]	0.85 (0.76; 0.96)	-0.13 (-0.23; -0.04)	
	80mg	Duloxetine 40mg	General Health Status ('very much better,' 'much better,' or 'a little better' from PGI-I)	(100/123) [93/123]	1.08 (0.94; 1.23)	0.06 (-0.05; 0.16)	
	80mg	Duloxetine 20mg		(100/123) [107/128]	0.97 (0.87; 1.09)	-0.02 (-0.12; 0.07)	
	40mg	Duloxetine 20mg	General Health Status ('very much better,' 'much better,' or 'a little better' from PGI-I)	(93/123) [107/128]	0.90 (0.80; 1.03)	-0.08 (-0.18; 0.02)	
	80mg	Duloxetine 40mg		(62/140) [51/137]	1.19 (0.89; 1.58)	0.07 (-0.04; 0.19)	
	80mg	Duloxetine 20mg	General Health Status ('very much better,' 'much better,' or 'a little better' from PGI-I)	(62/140) [43/138]	1.42 (1.04; 1.94)	0.13 (0.02; 0.24)	
	40mg	Duloxetine 20mg		(51/137) [43/138]	1.19 (0.86; 1.66)	0.06 (-0.05; 0.17)	

*Bold - significant relative risk at 95% confidence level. CST = cough stress test; NT = no treatment; PCT = positive cough stress test; PGI-I = Patient Global Impression of Improvement; PFMT = pelvic floor muscle training; SPT = stress pad test.

†not in the review (70).